Research
Psychedelic Research Opportunities for Mental Health in San Diego
Helping develop the next generation of advanced treatments through research is part of our mission at Kadima Neuropsychiatry
Research
Helping develop the next generation of advanced treatments through research is part of our mission at Kadima
Our Research
Kadima Neuropsychiatry conducts clinical trials of cutting-edge, experimental novel treatments for various mental health conditions, including depression and treatment-resistant depression, generalized anxiety disorder, and PTSD.
The experimental treatments that are currently, or soon to be, tested at KADIMA, for a variety of psychiatric conditions, include psilocybin, LSD, DMT, alternate form of ketamine, other medications with novel mechanisms of action, innovative medical devices, digital mental health apps, and virtual reality. We are currently enrolling to studies.
Psychedelic Research Substances We Explore:
LSD
Lysergic acid diethylamide
Psilocybin
“magic mushrooms”
5-MeO-DMT
5-methoxy-N,N-dimethyltryptamine
Active Research
We are currently enrolling for these clinical trials in San Diego:
Study assessing LSD for the Treatment of Anxiety Symptoms
Investigational Treatment: This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM-120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD). Learn more about the investigational treatment.
Study of Psilocybin for Treatment Resistant Depression
Investigational Treatment: A Phase III, multicentre, randomised, double-blind, placebo-controlled study to investigate the efficacy, safety, and tolerability of COMP360 (Psilocybin) in participants with treatment-resistant depression. Learn more about the investigational treatment.
Predict study-Using brain imaging to predict response to depression treatment
Investigational Treatment: Utilizing a revolutionary brain imaging device to assess and predict patients response to depression treatment.
Cognitive Behavioral Therapy (CBT) in adjunct with Deep Transcranial Magnetic Stimulation (dTMS) for Major Depressive Disorder (MDD)
Sponsor: Brainsway
Investigational Treatment: CBT-based, mobile-delivered, intervention platform. Learn more about the investigational treatment.
Effects of a Virtual Reality PsyAssist Calm Experience Program on Pre-treatment Anxiety Prior to Ketamine Dosing
Sponsor: TRIPP PsyAssist
Investigational Treatment: TRIPP PsyAssist is a virtual reality meditation program that aims to reduce pre-treatment anxiety in ketamine patients with anxiety symptoms. – Learn more about the investigational treatment
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) (RELIANCE-II)
Investigational Treatment: REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Learn more about the investigational treatment.
Study evaluating a Brain Neuromodulation system for the Treatment of Major Depressive Disorder (MDD).
Investigational Treatment: Relivion®DP is a non-invasive and multi-channel brain neuromodulation system for at home treatment of neurological and neuropsychiatric disorders – Learn more about the investigational treatment
Are You Interested in Participating in Clinical Research?
To sign up for potential participation in clinical research studies at Kadima, please fill out the following survey and provide your contact information.
Upcoming Research
Study of 5MeO-DMT for Treatment Resistant Depression
Study of Psilocybin for Generalized Anxiety Disorder
Study of Methylone for Post Traumatic Stress Disorder
Our Study Sponsors and Partners
Recently Completed Trials
Mind Medicine, MMED 120
Phase 2b of MMED 120 (LSD-tartrate) in participants with Generalized Anxiety Disorder. Read More
Compass Pathways, COMP001
The safety and efficacy of psilocybin in participants with Treatment Resistant Depression. Read More
Compass Pathways, COMP003
The safety and efficacy Of psilocybin as an adjunctive therapy in participants with Treatment Resistant Depression. Read More
Perception Neuroscience, Inc, PCN-101
The safety and efficacy of PCN-101 (R-Ketamine) in participants with Treatment Resistant Depression. Read More
Leave your details and we will contact you: